Comparison of the correlation between serum autoantibodies against aldehyde dehydrogenase 2 and thyrotropin receptor in patients with Graves' ophthalmopathy.
作者信息
Lin Chia-Ching, Chiu Li-Wen, Lee Po-Yen, Chen Kuo-Jen, Cheng Kai-Chun
机构信息
Department of Ophthalmology, Kaohsiung Municipal Siaogang Hospital, Kaohsiung, Taiwan.
Department of Ophthalmology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
出版信息
Indian J Ophthalmol. 2024 Feb 1;72(2):298-299. doi: 10.4103/IJO.IJO_673_23. Epub 2024 Jan 25.
Abstract
摘要
相似文献
1
Comparison of the correlation between serum autoantibodies against aldehyde dehydrogenase 2 and thyrotropin receptor in patients with Graves' ophthalmopathy.格雷夫斯眼病患者血清抗醛脱氢酶2自身抗体与促甲状腺激素受体之间相关性的比较。
Indian J Ophthalmol. 2024 Feb 1;72(2):298-299. doi: 10.4103/IJO.IJO_673_23. Epub 2024 Jan 25.
2
Stimulatory Thyrotropin Receptor Antibodies Are a Biomarker for Graves' Orbitopathy.刺激性促甲状腺素受体抗体是格雷夫斯眼病的生物标志物。
Front Endocrinol (Lausanne). 2021 Feb 2;11:629925. doi: 10.3389/fendo.2020.629925. eCollection 2020.
3
Relation between therapy options for Graves' disease and the course of Graves' ophthalmopathy: a systematic review and meta-analysis.格雷夫斯病治疗方案与格雷夫斯眼病病程的关系：一项系统评价和荟萃分析。
J Endocrinol Invest. 2016 Nov;39(11):1225-1233. doi: 10.1007/s40618-016-0484-y. Epub 2016 May 24.
4
Radioiodine therapy versus antithyroid medications for Graves' disease.放射性碘治疗与抗甲状腺药物治疗Graves病的比较。
Cochrane Database Syst Rev. 2016 Feb 18;2(2):CD010094. doi: 10.1002/14651858.CD010094.pub2.
5
Thyroid eye disease (Graves' orbitopathy): clinical presentation, epidemiology, pathogenesis, and management.甲状腺眼病（格雷夫斯眶病）：临床表现、流行病学、发病机制及管理
Lancet Diabetes Endocrinol. 2025 Jul;13(7):600-614. doi: 10.1016/S2213-8587(25)00066-X. Epub 2025 May 2.
6
Euthyroid Graves' ophthalmopathy with negative autoantibodies.自身抗体阴性的甲状腺功能正常的Graves眼病
J Natl Med Assoc. 2005 Nov;97(11):1547-9.
7
[Graves' ophthalmopathy].[格雷夫斯眼病]
Nihon Rinsho. 2006 May 28;Suppl 1:307-10.
8
Blocking the Thyrotropin Receptor with K1-70 in a Patient with Follicular Thyroid Cancer, Graves' Disease, and Graves' Ophthalmopathy.用 K1-70 阻断促甲状腺激素受体治疗滤泡性甲状腺癌、Graves 病和 Graves 眼病患者。
Thyroid. 2021 Oct;31(10):1597-1602. doi: 10.1089/thy.2021.0053. Epub 2021 Jul 8.
9
Assays for thyroid-stimulating antibodies and thyrotropin-binding inhibitory immunoglobulins in children with Graves' disease.格雷夫斯病患儿促甲状腺素刺激抗体和促甲状腺素结合抑制性免疫球蛋白检测
Endocr J. 2005 Oct;52(5):505-10. doi: 10.1507/endocrj.52.505.
10
Unilateral optic neuropathy as the initial manifestation of euthyroid Graves' disease.单侧视神经病变作为甲状腺功能正常的Graves病的首发表现。
Intern Med. 2009;48(22):1993-4. doi: 10.2169/internalmedicine.48.2372. Epub 2009 Nov 16.
引用本文的文献
1
A combined transcriptomics and proteomics approach reveals S100A4 as a potential biomarker for Graves' orbitopathy.一种结合转录组学和蛋白质组学的方法揭示了S100A4作为Graves眼病的潜在生物标志物。
Front Genet. 2024 Sep 18;15:1342205. doi: 10.3389/fgene.2024.1342205. eCollection 2024.
本文引用的文献
1
Disulfiram Exerts Antiadipogenic, Anti-Inflammatory, and Antifibrotic Therapeutic Effects in an Model of Graves' Orbitopathy.双硫仑在格雷夫斯眼眶病模型中发挥抗脂肪生成、抗炎和抗纤维化治疗作用。
Thyroid. 2022 Mar;32(3):294-305. doi: 10.1089/thy.2021.0246. Epub 2021 Dec 31.
2
Autoantibody against aldehyde dehydrogenase 2 could be a biomarker to monitor progression of Graves' orbitopathy.抗醛脱氢酶2自身抗体可能是监测格雷夫斯眼眶病进展的生物标志物。
Graefes Arch Clin Exp Ophthalmol. 2018 Jun;256(6):1195-1201. doi: 10.1007/s00417-017-3894-4. Epub 2018 Feb 3.
3
Clinical value of TSH receptor antibodies measurement in patients with Graves' orbitopathy.促甲状腺激素受体抗体检测在格雷夫斯眼病患者中的临床价值
Pediatr Endocrinol Rev. 2010 Mar;7 Suppl 2:198-203.
4
Graves' ophthalmopathy.格雷夫斯眼病。
N Engl J Med. 2010 Feb 25;362(8):726-38. doi: 10.1056/NEJMra0905750.
Zotero 插件